Education
About Us
Working with TipRanks
Follow Us
Pacific Biosciences (PACB)
NASDAQ:PACB
PACB Stock Chart & Stats
$2.23
$0.14(7.00%)
At close: 4:00 PM EST
$2.23
$0.14(7.00%)
Day’s Range― - ―
52-Week Range$0.85 - $2.73
Previous CloseN/A
Volume8.28M
Average Volume (3M)10.47M
Market Cap
$673.25M
Enterprise Value$786.21M
Total Cash (Recent Filing)$298.65M
Total Debt (Recent Filing)$703.08M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Feb 12, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding301,907,440
10 Day Avg. Volume10,034,810
30 Day Avg. Volume10,470,462
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)0.99
Price to Sales (P/S)3.26
P/FCF Ratio-2.37
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue5.09
Enterprise Value/Gross Profit20.02
Enterprise Value/Ebitda-7.60
Forecast
1Y Price Target
$2.30Price Target Upside3.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.86
Revenue Forecast (FY)$157.22M
Bulls Say, Bears Say
Bulls Say
Cost EfficiencyThe new SPRQ-Nx chemistry and multi-use SMRT cells will enable a nearly 40% reduction in cost to $300 per 20x genome on Revio compared to original SPRQ chemistry and SMRT cells.
Product InnovationPacBio's new multi-use SMRT cells could unlock larger projects for customers and benefit PACB's gross margin.
Strategic GrowthAnalyst remains optimistic that PacBio should overcome ongoing headwinds and is positioned to return to solid growth given its progress with clinical customers and population-scale programs.
Bears Say
Instrument SalesSales missed by (4%) due to weak instruments while consumables grew 15%.
Market ChallengesThe performance was impacted by lower Revio pricing and delayed Vega shipments.
Revenue GuidanceThe company narrowed its 2025 revenue guidance, lowering the midpoint, due to ongoing NIH budget uncertainty and lower-than-expected placements.
Pacific Biosciences News
PACB FAQ
What was Pacific Biosciences’s price range in the past 12 months?
Pacific Biosciences lowest stock price was $0.85 and its highest was $2.73 in the past 12 months.
What is Pacific Biosciences’s market cap?
Pacific Biosciences’s market cap is $673.25M.
When is Pacific Biosciences’s upcoming earnings report date?
Pacific Biosciences’s upcoming earnings report date is Feb 12, 2026 which is in 70 days.
How were Pacific Biosciences’s earnings last quarter?
Pacific Biosciences released its earnings results on Nov 05, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.151 by $0.021.
Is Pacific Biosciences overvalued?
According to Wall Street analysts Pacific Biosciences’s price is currently Undervalued.
Does Pacific Biosciences pay dividends?
Pacific Biosciences does not currently pay dividends.
What is Pacific Biosciences’s EPS estimate?
Pacific Biosciences’s EPS estimate is -0.15.
How many shares outstanding does Pacific Biosciences have?
Pacific Biosciences has 301,907,440 shares outstanding.
What happened to Pacific Biosciences’s price movement after its last earnings report?
Pacific Biosciences reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.151. Following the earnings report the stock price went down -7.292%.
Which hedge fund is a major shareholder of Pacific Biosciences?
Currently, no hedge funds are holding shares in PACB
Pacific Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.30 (3.14% Upside)
$2.30 (3.14% Upside)
Blogger Sentiment
Bearish
PACB Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.75%
12-Months-Change
Fundamentals
Return on Equity
-205.41%
Trailing 12-Months
Asset Growth
-44.61%
Trailing 12-Months
Company Description
Pacific Biosciences
Pacific Biosciences (PACB) is a biotechnology company specializing in the development and manufacture of innovative DNA sequencing technologies. Founded in 2004 and headquartered in Menlo Park, California, the company operates primarily in the genomics sector, providing high-quality, long-read sequencing solutions that empower researchers in various fields such as genomics, transcriptomics, and epigenomics. Its core products include the Sequel II and Sequel IIe systems, which are designed to deliver comprehensive and accurate genomic data for applications ranging from basic research to clinical diagnostics.
PACB Company Deck
PACB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive and negative aspects. While there were significant achievements in consumable revenue, gross margin improvements, and clinical advancements, these were tempered by an overall decline in total revenue and challenges in the funding environment impacting instrument sales.View all PACB earnings summariesPACB Stock 12 Month Forecast
Average Price Target
$2.30
▲(3.14% Upside)
Technical Analysis
Ownership Overview
2.37% Insiders
8.37% Mutual Funds
19.28% Other Institutional Investors
48.56% Public Companies and
Individual Investors